OTCMKTS:GBLX

GB Sciences Stock Forecast, Price & News

$0.05
0.00 (0.00 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.05
▼
$0.06
50-Day Range
$0.04
▼
$0.07
52-Week Range
$0.02
▼
$0.13
Volume296,893 shs
Average Volume695,098 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GBLX News and Ratings via Email

Sign-up to receive the latest news and ratings for GB Sciences and its competitors with MarketBeat's FREE daily newsletter.


GB Sciences logo

About GB Sciences

GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Headlines

GB Sciences Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
June 17, 2021 |  finance.yahoo.com
Short Interest in GB Sciences, Inc. (OTCMKTS:GBLX) Declines By 96.5%
Short Interest in GB Sciences, Inc. (OTCMKTS:GBLX) Declines By 96.5%
June 11, 2021 |  americanbankingnews.com
GB Sciences (OTCMKTS:GBLX) Stock Price Passes Above Fifty Day Moving Average of $0.05
GB Sciences (OTCMKTS:GBLX) Stock Price Passes Above Fifty Day Moving Average of $0.05
June 4, 2021 |  americanbankingnews.com
GB Sciences (OTCMKTS:GBLX) Stock Crosses Below Fifty Day Moving Average of $0.05
GB Sciences (OTCMKTS:GBLX) Stock Crosses Below Fifty Day Moving Average of $0.05
May 27, 2021 |  americanbankingnews.com
GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation Forum
GB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum
April 27, 2021 |  finance.yahoo.com
GB Sciences, Inc.: GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
GB Sciences, Inc.: GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
April 20, 2021 |  finanznachrichten.de
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
April 20, 2021 |  finance.yahoo.com
GB Sciences, Inc.: GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
GB Sciences, Inc.: GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
April 7, 2021 |  finanznachrichten.de
GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief
GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief
March 23, 2021 |  finance.yahoo.com
GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndr
GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndr
January 27, 2021 |  bloomberg.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.50 out of 5 stars

Medical Sector

1655th out of 2,097 stocks

Biotechnology Industry

48th out of 86 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GB Sciences (OTCMKTS:GBLX) Frequently Asked Questions

What stocks does MarketBeat like better than GB Sciences?

Wall Street analysts have given GB Sciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GB Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GB Sciences?

GB Sciences saw a drop in short interest during the month of May. As of May 28th, there was short interest totaling 500 shares, a drop of 96.5% from the May 13th total of 14,300 shares. Based on an average daily trading volume, of 264,300 shares, the days-to-cover ratio is presently 0.0 days.
View GB Sciences' Short Interest.

How were GB Sciences' earnings last quarter?

GB Sciences, Inc. (OTCMKTS:GBLX) announced its earnings results on Monday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter.
View GB Sciences' earnings history.

How has GB Sciences' stock price been impacted by Coronavirus (COVID-19)?

GB Sciences' stock was trading at $0.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GBLX shares have increased by 80.0% and is now trading at $0.0540.
View which stocks have been most impacted by COVID-19.

Who are GB Sciences' key executives?

GB Sciences' management team includes the following people:
  • Mr. John C. Poss, Chairman & CEO (Age 73, Pay $157.5k)
  • Mr. Zach Swarts, Interim Chief Financial Officer (Age 33, Pay $160k)
  • Dr. Andrea Small-Howard M.B.A., Ph.D., MBA, Member of Scientific Advisory Board, Chief Science Officer & Director (Age 52, Pay $160k)
  • Mr. Krin Ellery Kuethe, Sr. VP of Cultivation (Age 37)
  • Dr. Michael Farley, Exec. VP of Corp. Devel., GBS Global Biopharma, Inc.

Who are some of GB Sciences' key competitors?

Some companies that are related to GB Sciences include Canopy Growth (WEED), Innovative Industrial Properties (IIPR), Leaf Mobile (LEAF), GrowGeneration (GRWG), OrganiGram (OGI), 22nd Century Group (XXII), Emblem (EMC), ICC Labs (ICC), Bioventix (BVXP), KushCo (KSHB), Terra Tech (TRTC), General Cannabis (CANN), Net Savings Link (NSAV), MassRoots (MSRT) and Grow Capital (GRWC).
View all of GBLX's competitors.

What other stocks do shareholders of GB Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GB Sciences investors own include KushCo (KSHB), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MassRoots (MSRT), Surna (SRNA), Gran Tierra Energy (GTE), GreenGro Technologies (GRNH), MariMed (MRMD), Pennsylvania Real Estate Investment Trust (PEI) and PotNetwork (POTN).

What is GB Sciences' stock symbol?

GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."

How do I buy shares of GB Sciences?

Shares of GBLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GB Sciences' stock price today?

One share of GBLX stock can currently be purchased for approximately $0.05.

How many employees does GB Sciences have?

GB Sciences employs 23 workers across the globe.

What is GB Sciences' official website?

The official website for GB Sciences is gbsciences.com.

Where are GB Sciences' headquarters?

GB Sciences is headquartered at 6450 Cameron St Ste 110A, LAS VEGAS, NV 89118-4337, United States.

How can I contact GB Sciences?

GB Sciences' mailing address is 6450 Cameron St Ste 110A, LAS VEGAS, NV 89118-4337, United States. The company can be reached via phone at +1-888-8953594.


This page was last updated on 6/20/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.